For the second quarter (interim) of the fiscal year ending March 2027, revenue was 181,853 million yen, operating income was 36,335 million yen, and interim profit was 22,623 million yen. Year-over-year, revenue increased by 6.4%, operating income increased by 1.0%, while interim profit decreased by 10.7%. By segment, the Medical Platform performed well, while Site Solutions saw margin pressure due to lower unit prices and upfront investments. Full-year dividend forecast is TBD. An earnings presentation is scheduled.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2413","jir_company_name":"M3, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-04","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2413-20261104-01.pdf","jir_short_summary":"For the second quarter (interim) of the fiscal year ending March 2027, revenue was 181,853 million yen, operating income was 36,335 million yen, and interim profit was 22,623 million yen. Year-over-year, revenue increased by 6.4%, operating income increased by 1.0%, while interim profit decreased by 10.7%. By segment, the Medical Platform performed well, while Site Solutions saw margin pressure due to lower unit prices and upfront investments. Full-year dividend forecast is TBD. An earnings presentation is scheduled.","jir_summary":"### Performance Overview\nM3's consolidated results for the second quarter (interim) of the fiscal year ending March 2027 showed revenue of 181,853 million yen, an increase of 6.4% year-over-year. Operating income was 36,335 million yen, up 1.0%, pre-tax profit was 36,620 million yen, and interim profit was 22,623 million yen, declining from the prior year. By segment, Medical Platform and overseas operations remained solid, while Site Solutions faced profit compression due to the impact of medical fee revisions and new investments. Supplemental materials to the financial summary will be published on the same day, and an earnings presentation will be held.\n\n### Shareholder Returns and Outlook\nThe full-year dividend forecast for the fiscal year ending March 2027 is TBD. The company will determine future shareholder distributions based on funding needs and cash flow. The number of treasury shares at the interim period-end has not increased, and shareholder returns will continue to be monitored. The financial summary explicitly states there are no revisions to the full-year earnings guidance for fiscal 2027.","jir_financial_highlights":"Revenue: 181,853 million yen (Year-over-Year +6.4%)\nOperating Income: 36,335 million yen (Year-over-Year +1.0%)\nInterim Profit: 22,623 million yen (Year-over-Year -10.7%)\nSegment Revenue (Medical Platform): 54,384 million yen (Year-over-Year +4.6%)\nSegment Revenue (Site Solutions): 28,735 million yen (Year-over-Year +9.3%)\nOverseas Segment Revenue: 45,447 million yen (Year-over-Year +10.7%)","jir_category":"","jir_hashtags":"#M3, #Earnings, #Interim, #HealthcareIT, #SegmentPerformance","jir_key_figures":"Revenue: 181,853 million yen\nOperating Income: 36,335 million yen\nInterim Profit: 22,623 million yen","jir_meta_title":"M3, Inc. Q2 FY2027 Financial Summary | Revenue 181,853 million yen, Operating Income 36,335 million yen","jir_meta_description":"M3, Inc. Q2 FY2027 financial summary: revenue 181,853 million yen (+6.4% YoY), operating income 36,335 million yen (+1.0%), interim profit 22,623 million yen. Analysis of segment trends and the company's dividend policy.","jir_og_title":"M3, Inc. Interim Results FY2027: Revenue 181,853 million yen, Operating Income 36,335 million yen","jir_og_description":"Highlights of M3, Inc.'s second quarter results, including revenue growth of just over 4% year-over-year, segment performance, and an undecided dividend policy.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[170885,181853,Unknown]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2026-04\\\",\\\"2026-07\\\",\\\"2026-10\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[35992,36335,Unknown]}]},\\\"options\\\":{}}\"}]","ir_related_company":7464,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-141098","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n